Avalyn Pharma Inc. Common Stock (AVLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avalyn Pharma Inc. Common Stock (AVLN) has a cash flow conversion efficiency ratio of 0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.89 Million) by net assets ($-264.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View AVLN live share price for real-time trading data and today's change.
Avalyn Pharma Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Avalyn Pharma Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Avalyn Pharma Inc. Common Stock (AVLN) market capitalisation for the company's overall valuation and market capitalisation.
Avalyn Pharma Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avalyn Pharma Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Avalyn Pharma Inc. Common Stock (AVLN) total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allied Machinery Co. Ltd.
SHG:605060
|
N/A |
|
Tamilnad Mercantile Bank Limited
NSE:TMB
|
-0.323x |
|
Qinchuan Machine Tool & Tool Group Share Co Ltd
SHE:000837
|
0.028x |
|
Yantai Zhenghai Magnetic Mat
SHE:300224
|
0.015x |
|
Henan Hanwei Electronics Co
SHE:300007
|
-0.020x |
|
Fluence Energy Inc
NASDAQ:FLNC
|
-0.465x |
|
Prudent Corporate Advisory Services Limited
NSE:PRUDENT
|
0.133x |
|
North Electro-Optic Co Ltd
SHG:600184
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Avalyn Pharma Inc. Common Stock from 2024 to 2025. Review Avalyn Pharma Inc. Common Stock free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-238.66 Million | $-81.48 Million | 0.341x | +23.19% |
| 2024-12-31 | $-174.52 Million | $-48.37 Million | 0.277x | -- |
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more